Using in vivo models, we have implicated the ST3Gal1-sialoglycan-Siglec axis in macrophage anti-tumour biology and provide proof-of-concept data suggesting that depleting ST3Gal1 associated sialoglycans or targeting their respective Siglecs may boost immune tumour clearance. The gene discussed is ST3GAL1; the disease is neoplasm.